Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.90 |
| ▸ | PSMB1 | P20618 | 8/20 | 0.71 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.71 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.71 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 3/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681637 | 0.99 | KDM4E (0.92) | KDM4EPSMB1PSMB5PSMB2LTA4H | |
| Hydrochloric Acid SCHEMBL8693860 | 0.97 | KDM4E (0.90) | KDM4EPSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL2089311 | 0.93 | KDM4E (0.78) | KDM4EPSMB1PSMB5PSMB2MAPT | |
| SCHEMBL491928 | 0.92 | KDM4E (0.81) | KDM4EPSMB1PSMB5PSMB2MAPT | |
| SCHEMBL63569 | 0.87 | SMN1; SMN2 (0.72) | KDM4EPSMB1PSMB5MAPTHRH3 | |
| Hydrochloric Acid SCHEMBL23247221 | 0.86 | KDM4E (0.69) | KDM4EPSMB1PSMB5PSMB2LTA4H | |
| Hydrochloric Acid SCHEMBL20575882 | 0.86 | SMN1; SMN2 (0.70) | KDM4EPSMB1PSMB5MAPTHRH3 | |
| SCHEMBL21408538 | 0.86 | HRH3 (0.79) | KDM4EPSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL63672 | 0.85 | KDM4E (0.67) | KDM4EPSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL6534752 | 0.85 | KDM4E (0.77) | KDM4EPSMB1PSMB5PSMB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420529-A | Novel estrogen receptor down-regulator compound, preparation method and application | 南京中医药大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2526116-B1 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN | ST GEORGES HOSP MEDICAL SCHOOL (GB) | 2015-05-13 | — | — | EP | disclosed |
| EP-1019047-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6541499-B1 | Antithrombotic agents | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6518267-B1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | disclosed |
| EP-1019047-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1067894-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1019047-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999059526-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1998048800-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5648368-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | KDM4E 2081/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | KDM4E 2081/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | KDM4E 2081/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | KDM4E 2081/4885PSMB1 3099/4885PSMB5 2901/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | KDM4E 2081/4885PSMB1 3099/4885PSMB5 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.